Targeted Fluorescence Imaging in AMD
NCT05262244
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Age-Related Macular Degeneration
NAMD
Interventions
DRUG:
Bevacizumab-IRDye800CW
Sponsor
University Medical Center Groningen